On October 8th, I had the pleasure of visiting Genfit, a biopharmaceutical company based in Lille, France, specializing in the discovery and development of innovative therapies for liver diseases, with a particular focus on rare and severe liver conditions.
During this visit, I had the opportunity to present a range of Revvity solutions supporting liver disease research, highlighting how our technologies can help scientists investigate biological mechanisms, monitor cellular responses, and evaluate therapeutic strategies.
Here are the key topics we explored:
🧪 HTRF® amp; AlphaLISA® — An overview of our latest kits, illustrated with concrete study cases from application notes, demonstrating how these technologies can support a wide range of research applications.
🧬 Lumi® / LEGENDplex™ — Multiplex cytokine profiling, enabling the simultaneous measurement of up to 13 cytokines to better characterize inflammatory responses.
🔬 pHSense™ — A tool for studying the internalization of receptors, antibodies, and antibody-drug conjugates (ADCs), providing valuable insights into cellular uptake mechanisms.
🧫 ATPLite™ 1step — A luminescence-based solution for assessing cell viability in both 2D and 3D models, supporting research with physiologically relevant cellular systems.
A big thank you to my colleague Sabine BerrangerERRANGER from our sales team for her collaboration, and to Simon Debaeckerker and his team at Genfit for organizing this event and welcoming us!
#Revvity #Genfit #LiverDisease #DrugDiscovery #HTRF #AlphaLISA #LEGENDplex #pHSense #CellViability #LifeSciences #Biotechnology
